Devon Ksiazk, PA
Physician Assistant · Westerville, OHNPI 1619244696
Payments from drug & device makers
Across 312 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$805
- Novo Nordisk$607
- Dexcom, Inc.$369
- Boehringer Ingelheim$331
- Lilly USA, LLC$320
- AbbVie$249
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,952100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 56 | $805 |
| Novo Nordisk | 66 | $607 |
| Dexcom, Inc. | 11 | $369 |
| Boehringer Ingelheim | 21 | $331 |
| Lilly USA, LLC | 29 | $320 |
| AbbVie | 15 | $249 |
| Insulet Corporation | 8 | $244 |
| Amgen | 10 | $231 |
| Abbott | 12 | $219 |
| Corcept Therapeutics | 9 | $190 |
| Xeris Pharmaceuticals, Inc. | 9 | $169 |
| Bayer | 6 | $132 |
| Radius Health, Inc. | 6 | $132 |
| Sanofi-aventis U.S. LLC | 6 | $123 |
| Tandem Diabetes Care, Inc. | 8 | $113 |
| AstraZeneca(2 entities) | 6 | $91 |
| Amneal Pharmaceuticals LLC | 2 | $82 |
| Antares Pharma, Inc. | 4 | $80 |
| Novartis | 4 | $80 |
| Pfizer | 3 | $64 |
| Medtronic | 2 | $56 |
| BETA Bionics, Inc. | 4 | $48 |
| IBSA Pharma Inc. | 2 | $37 |
| Cequr Corporation | 3 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Amarin Pharma, Inc. | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $23 |
| Chiesi USA, Inc. | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Lifescan, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Clarus Therapeutics Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$221
- AFREZZA$125
How this compares
$4,962 in reported general payments places this provider in the 90th percentile of 4,098 physician assistant providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 164 | $258,360 |
| MounjaroTirzepatide | 112 | $179,388 |
| TrulicityDulaglutide | 51 | $77,132 |
| JardianceEmpagliflozin | 51 | $69,840 |
| FarxigaDapagliflozin Propanediol | 34 | $43,437 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $40,185 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $37,683 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $35,069 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $19,968 |
| JanuviaSitagliptin Phosphate | 19 | $18,841 |
| Repatha SureclickEvolocumab | 17 | $17,441 |
| Gvoke Hypopen 2-PackGlucagon | 29 | $17,271 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 20 | $17,073 |
| VascepaIcosapent Ethyl | 11 | $10,049 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $9,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $320 | $266,154184 claims |
| Novo NordiskOzempic | $607 | $258,360164 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $331 | $89,80768 claims |
| AstraZenecaFarxiga | $91 | $43,43734 claims |
| AbbVieSynthroid | $249 | $8,40392 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $82 | $1,229125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,098 physician assistant providers in Ohio.
Other physician assistant in Westerville
- Steven WurzelbacherCincinnati$309K
- Emily AnkromDayton$192K
- Amanda MaggartWorthington$164K
- Megan SevillaMayfield Heights$132K
- Erin StrculaBelpre$106K
- Natalie WalkupSylvania$105K
- Sarah LaubNew Albany$100K
- Jessica RhominskiCanal Winchester$78K
- Alan OdonnellCincinnati$71K
- Brook GramBeloit$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.